Echo | Angio | ECG | X-Ray/MRI | Clinical Trials | Guidelines | Drug Info |  Journals  | Events | Interesting Cases

Welcome May 22, 2013
Search News by Date
  



Significantly decreased degree of mitral regurgitation or an improved mitral regurgitation, reverse remodeling of left atrium and decrease in left atrium diameters are the benefits with cardiac resynchronization therapy

Studies have shown that resynchronization of the ventricles leads to reduction of functional mitral regurgitation and to a better clinical profile. To throw more light onto this, Dr. M Petrovic and coworkers performed the present trial that assessed the positive effects of resynchronization therapy on reduction of mitral insufficiency in their responders' group, as it was shown to be associated with dyssynchrony improvement and left ventricular reverse remodeling after resynchronization at mid-term follow-up.

Study population for this trial included 57 patients (80% men) with idiopathic dilated cardiomyopathy and standard inclusion criteria (New York Heart Association class-NYHA class III or IV heart failure, left ventricular ejection fraction ≤ 35%, QRS ≥120 ms, and optimal medical therapy).

As a part of this study, researchers evaluated the clinical status and echocardiographic parameters (conventional and tissue Doppler imaging) before and at 12 months after the CRT. All-cause mortality and change in NYHA class comprised the clinical outcome.

Findings from this study showed an echocardiographic left ventricular reverse remodeling (end-systolic volume decreased more than 15 %) was reported by 54% of the 57 patients (average age was 59. 9 years) and were responders to CRT.

At 12 months follow-up in responders' group, a statistically significant decrease in PISA radius and a significant decrease in mitral regurgitation velocity-time integral, PISA and the peak velocity of mitral regurgitation were observed (table 1).

Table 1:  Responders group vs. Non responders group

 

PISA radius Mitral regurgitation velocity-time integral PISA peak velocity of mitral regurgitation
Non responders group 0.64 ±0.15cm 1.3 ±0.4cm 2.4±0.9 cm2 4.4±0.7m/s
Responders group 0.4±0.25cm 1.0±0.5cm 1.8±1.6cm2 3.9±0.9m/s
P values 0.011 <0.05    

Also, significantly decreased degree of mitral regurgitation as assessed by color Doppler was reported (p<0.01). Additionally, there was a significant association of an improvement of mitral regurgitation with the shortening of interventricular mechanical delay and septal-to-lateral wall delay (table), as was reverse remodeling of left atrium and decrease in left atrium diameters, p<0.05.

Table 2: Improvement of mitral regurgitation and reverse remodeling of left atrium and decrease in left atrium diameters

  Interventricular mechanical delay Septal-to-lateral wall delay
Before 12 months follow up 60.7±25ms 105±52 ms
At 12 months follow up 32.5±28ms 36±47 ms
P values <0.001 <0.001

Furthermore, all of responders had a statistically changed NYHA class with an improved clinical status. Higher survival rate was reported in responders group.

Based on all the above findings, this study concluded that the reduction in mitral regurgitation after the resynchronization therapy was associated with left ventricular reverse remodeling and dyssynchrony improvement at mid-term follow up. This reduction contributed to a better clinical status of responders.

 


Source:HEART FAILURE 2012
Compiled and edited by the Editorial team and approved by Expert panel of CardioValens.com

 Other News
First study to evaluate the effectiveness of Functional Electrical Stimulation on exercise capacity, endothelial function and echocardiographic indices of diastolic function in chronic heart failure patients with preserved systolic function
Higher predictive value for malignant ventricular arrhythmias and complex end point for patients with dilated nonischaemic cardiomyopathy and chronic heart failure
Association between hyperglycemia and adverse outcomes observed in AMI patients does not hold true in patients hospitalized with other cardiovascular conditions
Presence of septal asymmetric Hypertrophic cardiomyopathy type is the only independent predictor of increased right atrial volume index
Excellent post-transplant outcomes with mechanical circulatory support as bridge to heart transplantation
Myocardial lipid content correlates inversely with left ventricular function in heart failure patients with type 2 diabetes
Periodic use of levosimendan in outpatients with end-stage chronic heart failure is safe and effective in improving quality of life and in reducing re-admissions for worsening heart failure at least in the first eight months of therapy
Highly prevalent severe interatrial mechanical delay in heart failure with preserved ejection fraction is associated with shorter mitral A wave and higher filling pressures
Presence of microalbuminuria is a potential risk marker of events in patients admitted with ACS
The CARILLION® Mitral Contour System implanted in heart failure patients with functional mitral regurgitation provide clinical improvements
Digoxin in high risk Heart Failure patients with reduced ejection fractions
Co-relation between blood pressure/body composition and exercise in hypertensive older overweight individuals
Gender wise analysis of hypertensive patients under a stabilized therapy and without a history of cardiovascular events shows significant differences in the prediction of either stroke or global cardiovascular events or even both
Hygia Project: ingestion of full doses of hypertension medications at bedtime is a proper chronotherapeutic approach and shown to result in improved ambulatory BP control and fewer cardiovascular events
ARB-based aggressive antihypertensive therapy guided by home BP monitoring in patients with diabetes/pre-diabetes is effective in improving cardiovascular target damage
Hypoadiponectinemia and high aldosterone levels in arterial rigidity are responsible for resistance to an antihypertensive therapy
Total cholesterol control can be predicted by only younger age for management of childhood dyslipidemia and hypertension and prevention
Impact of the Combination Antihypertensive Therapy with inclusion of Atorvastatin and Metformin on insulin resistance parameters in patients with the metabolic syndrome and fasting hyperinsulinemia
The combination treatment with Telmisartan, Torasemid and Atorvastatin has positive effects on blood pressure levels and reduces the intensity of heart failure progression in hypertensive's with heart failure class II-III NYHA
Subjects with masked hypertension have an early alteration of diastolic dysfunction
Associations of an increasing plasma insulin levels in patients with metabolic syndrome and post-infarction cardio-sclerosis
Reflected pressure waves in the arm in contrast to central systolic BP do not contribute to the measured arm cuff systolic BP measurements except in Stage 2 hypertension and thereby do not typically influence the diagnosis or staging of systolic hypertension

About Us | Disclaimer |  Privacy Statement | Advertising Info 
info@centrixhealthcare.com © Copyright 2000-2013 Centrix Healthcare Inc. - All Rights Reserved.